• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    8/14/25 5:32:16 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Roivant Sciences Ltd.

    (Name of Issuer)


    Common Shares, $0.0000000341740141 par value per share

    (Title of Class of Securities)


    G76279101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    34,237,779.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    34,237,779.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    34,237,779.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.02 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    VIKING GLOBAL PERFORMANCE LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    18,346,865.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    18,346,865.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,346,865.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Global Equities II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    366,938.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    366,938.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    366,938.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Global Equities Master Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    17,979,927.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    17,979,927.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    17,979,927.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.6 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Long Fund GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,384,710.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,384,710.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,384,710.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Long Fund Master Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,384,710.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,384,710.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,384,710.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,506,204.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,506,204.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,506,204.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,506,204.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,506,204.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,506,204.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,506,204.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,506,204.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,506,204.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    9,506,204.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    9,506,204.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,506,204.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    34,237,779.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    34,237,779.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    34,237,779.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.02 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Ott David C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    34,237,779.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    34,237,779.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    34,237,779.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.02 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    G76279101


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    34,237,779.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    34,237,779.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    34,237,779.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.02 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Roivant Sciences Ltd.
    (b)Address of issuer's principal executive offices:

    7th Floor, 50 Broadway, London, United Kingdom, SW1H 0DB
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Performance LLC ("VGP"), Viking Global Equities II LP ("VGEII"), Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund GP LLC ("VLFGP"), Viking Long Fund Master Ltd. ("VLFM"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI and VGEII are Delaware limited partnerships; VGP, VLFGP, Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGEM and VLFM are Cayman Islands exempted companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
    (d)Title of class of securities:

    Common Shares, $0.0000000341740141 par value per share
    (e)CUSIP No.:

    G76279101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    VGI: 34,237,779 VGI provides managerial services to VGEII, VGEM, VLFM and VGOP. VGI has the authority to dispose of and vote the Common Shares directly owned by VGEII, VGEM, VLFM and VGOP. VGI does not directly own any Common Shares. Based on Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the Common Shares directly held by VGEII, VGEM, VLFM and VGOP. VGP: 18,346,865 VGP, as the general partner of VGEII, has the authority to dispose of and vote the Common Shares directly owned by VGEII. VGP serves as investment manager to VGEM and has the authority to dispose of and vote the Common Shares directly owned by VGEM. VGP does not directly own any Common Shares. Based on Rule 13d-3 under the Act, VGP may be deemed to beneficially own the Common Shares directly held by VGEII and VGEM. VGEII: 366,938 VGEII has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEII. VGEM: 17,979,927 VGEM has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM. VLFGP: 6,384,710 VLFGP serves as the investment manager of VLFM and has the authority to dispose of and vote the Common Shares directly owned by VLFM. VLFGP does not directly own any Common Shares. Based on Rule 13d-3 under the Act, VLFGP may be deemed to beneficially own the Common Shares directly held by VLFM. VLFM: 6,384,710 VLFM has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM. Opportunities Parent: 9,506,204 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the Common Shares controlled by Opportunities Portfolio GP, which consists of the Common Shares directly held by VGOP. Opportunities Parent does not directly own any Common Shares. Based on Rule 13d-3 under the Act, Opportunities Parent may be deemed to beneficially own the Common Shares directly held by VGOP. Opportunities GP: 9,506,204 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the Common Shares controlled by Opportunities Portfolio GP, which consists of the Common Shares directly held by VGOP. Opportunities GP does not directly own any Common Shares. Based on Rule 13d-3 under the Act, Opportunities GP may be deemed to beneficially own the Common Shares directly held by VGOP. Opportunities Portfolio GP: 9,506,204 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the Common Shares directly owned by VGOP. Opportunities Portfolio GP does not directly own any Common Shares. Based on Rule 13d-3 under the Act, Opportunities Portfolio GP may be deemed to beneficially own the Common Shares directly held by VGOP. VGOP: 9,506,204 VGOP has the authority to dispose of and vote the Common Shares directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 34,237,779 Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI), VGP, VLFGP and Opportunities Parent, have shared authority to dispose of and vote the Common Shares beneficially owned by VGI, VGP, VLFGP and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any Common Shares. Based on Rule 13d-3 under the Act, each may be deemed to beneficially own the Common Shares directly held by VGEII, VGEM, VLFM and VGOP. Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 34,237,779 Common Shares consisting of (i) 366,938 Common Shares directly and beneficially owned by VGEII, (ii) 17,979,927 Common Shares directly and beneficially owned by VGEM, (iii) 6,384,710 Common Shares directly and beneficially owned by VLFM and (iv) 9,506,204 Common Shares directly and beneficially owned by VGOP.
    (b)Percent of class:

    The percentages set forth herein are based on 682,229,832 Common Shares outstanding as of June 30, 2025, as reported by the Issuer in its quarterly report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the "Commission") on August 11, 2025. VGI: 5.02% VGP: 2.7% VGEII: 0.1% VGEM: 2.6% VLFGP: 0.9% VLFM: 0.9% Opportunities Parent: 1.4% Opportunities GP: 1.4% Opportunities Portfolio GP: 1.4% VGOP: 1.4% O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 5.02%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 VGP: 0 VGEII: 0 VGEM: 0 VLFGP: 0 VLFM: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 34,237,779 VGP: 18,346,865 VGEII: 366,938 VGEM: 17,979,927 VLFGP: 6,384,710 VLFM: 6,384,710 Opportunities Parent: 9,506,204 Opportunities GP: 9,506,204 Opportunities Portfolio GP: 9,506,204 VGOP: 9,506,204 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 34,237,779

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 VGP: 0 VGEII: 0 VGEM: 0 VLFGP: 0 VLFM: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 34,237,779 VGP: 18,346,865 VGEII: 366,938 VGEM: 17,979,927 VLFGP: 6,384,710 VLFM: 6,384,710 Opportunities Parent: 9,506,204 Opportunities GP: 9,506,204 Opportunities Portfolio GP: 9,506,204 VGOP: 9,506,204 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 34,237,779

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Investors LP (1)(2)(3)
    Date:08/14/2025
     
    VIKING GLOBAL PERFORMANCE LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Performance LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Equities II LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Equities Master Ltd.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)
    Date:08/14/2025
     
    Viking Long Fund GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Long Fund Master Ltd.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
    Date:08/14/2025
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:08/14/2025
     
    Ott David C.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
    Date:08/14/2025
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
    Date:08/14/2025

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $ROIV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    7/10/2025$19.00Buy
    Goldman
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    10/27/2022$7.00Overweight
    JP Morgan
    5/23/2022$6.00Outperform
    SVB Leerink
    More analyst ratings

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and Vant Chair Torti Frank was granted 13,736,547 shares (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    8/1/25 9:12:33 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & Immunovant CEO Venker Eric was granted 198,413 shares, increasing direct ownership by 14% to 1,660,636 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    8/1/25 9:09:54 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Pulik Richard covered exercise/tax liability with 1,919 shares, decreasing direct ownership by 0.48% to 397,553 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    7/30/25 9:00:43 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Roivant Sciences with a new price target

    Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00

    7/10/25 9:00:08 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Roivant Sciences with a new price target

    Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00

    2/15/24 6:44:53 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Roivant Sciences with a new price target

    Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00

    1/5/24 8:43:06 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

    BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in dermatomyositis (DM) remains on track for topline data readout in the second half of calendar year 2025, with last patient last visit completed in July; Roivant and Priovant hosted an investor event on brepocitinib in June to share details about the ongoing VALOR study, including pooled/blinded baseline data, clinical endpoints details and successful steroid tapering dataBrepocitinib program continues to advance with rapid enrollment in non-infe

    8/11/25 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

    BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call. About

    7/28/25 4:05:00 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

    Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulmonary diseases and a Roivant (NASDAQ:ROIV) company, today announced the publication of Phase 1 pharmacokinetics (PK) in healthy male volunteers following the administration of mosliciguat,

    6/16/25 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    8/14/25 5:32:16 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    8/14/25 4:39:28 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Roivant Sciences Ltd.

    10-Q - Roivant Sciences Ltd. (0001635088) (Filer)

    8/11/25 7:31:17 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Financials

    Live finance-specific insights

    View All

    $ROIV
    Leadership Updates

    Live Leadership Updates

    View All

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

    BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in dermatomyositis (DM) remains on track for topline data readout in the second half of calendar year 2025, with last patient last visit completed in July; Roivant and Priovant hosted an investor event on brepocitinib in June to share details about the ongoing VALOR study, including pooled/blinded baseline data, clinical endpoints details and successful steroid tapering dataBrepocitinib program continues to advance with rapid enrollment in non-infe

    8/11/25 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

    BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call. About

    7/28/25 4:05:00 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

    BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM. To access the video conference, please register online using this registration link. The presentation and conference details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcas

    6/9/25 4:05:00 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

    3/26/24 6:22:00 PM ET
    $PGTI
    $ROIV
    $RUN
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

    11/10/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

      BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

    10/13/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 4:58:58 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Roivant Sciences Ltd.

    SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 10:34:18 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care